Introduction {#s1}
============

One of public health\'s most cost-effective interventions to prevent and reduce the disease burden of infectious disease is vaccination. It is well-established that immunological memory stored in antigen-specific B cell repertoires frequently forms the foundation of successful natural or vaccine-induced immune protection ([@B1]). During the acute phase of pathogen exposure, naïve B cells enter germinal centers and undergo immunoglobulin (Ig) receptor somatic hypermutation (SHM) to increase antigen binding, isotype class switching to IgG or IgA for effector activities, and differentiation to short-lived antibody secreting plasmablasts or to long-lived plasma and memory B cells ([@B2]). Successful diversification of B cell clones and their corresponding Ig receptors creates clonal families, each a cluster or lineage of related antibodies all descended from the naïve B cell ancestor ([@B3]), and possessing variations in antigen binding and functional activities. Antibodies secreted from plasma cells, which mainly reside in the bone marrow, provide steady state protection against repeat infections. In contrast, memory B cells survive in a functionally quiescent state in tissues and can be found at low frequency in PBMCs after a pathogen is eliminated, re-activating and differentiating into antibody secreting plasmablasts within a week of a secondary infection ([@B4]--[@B6]). Evaluating both types of adaptive B-cell memory is challenged by the anatomical inaccessibility and rarity of these cells. A variety of serological assays for polyclonal antibody measurements have been developed ([@B7]) and, more recently, the applications of next generation sequencing (NGS) and single cell sequencing technologies have offered high resolution data on B cell antibody responses in peripheral blood samples ([@B8]). Computational algorithms to interpret genetic relationships between the millions of NGS B cell receptor (BCR) sequences have been developed to assign clonal families and help reconstruct *in vivo* B cell clonal lineages ([@B9]). However, outside of the acute phase of exposure, the depth of antigen-experienced B cell repertoires is still limited by the low frequency and relative transcriptional silence of memory B cells circulating in human blood.

The maintenance of memory B cells *in vivo* in the absence of persisting antigen has been proposed to occur through polyclonal stimulation mechanisms including: (i) Toll-like receptor (TLR) microbial agonists such as lipopolysaccharide (TLR4 agonist) or unmethylated single-stranded DNA motifs (e.g., CpG-B, a TLR9 agonist); and (ii) T cell bystander activation via CD40 ligation and cytokine production ([@B10]). When memory B cells are polyclonally activated *in vitro* independent of BCR signals, they proliferate and differentiate to plasma cells while maintaining specific antigen binding ([@B10]). There is no direct evidence excluding SHM in the BCRs using this technique, and the optimal combination of microbial products, cytokines, and feeder cells determined varies between labs ([@B10]--[@B12]). However, polyclonal stimulation of PBMCs is frequently applied with ELISPOT techniques to quantitate the total number of cells secreting IgG and report percentages of antigen-specific cells in response to vaccination. The specificity of the *in vitro* response for memory B cells has been supported by (i) the retention of signal to the relevant antigen and lack of signal to an irrelevant antigen; (ii) the absence of antigen-specific cell spots in unvaccinated, naïve blood donor PBMCs; and, (iii) positive ELISPOTs from cultures where CD19^+^CD20^+^ B cells were first depleted from PBMC and reconstituted with CD27^+^ (memory), but not CD27^−^ (naïve), B cells. Furthermore, broadly cross-reactive binding and neutralizing recombinant antibodies directed to Influenza A and HCMV from polyclonally stimulated PBMCs have been cloned from single B cells using this method ([@B12]).

Herein, we show the benefit of combining NGS with *in vitro* cell culture methods that functionally and selectively expand memory B cells within PBMC samples using CpG-B stimulation and cytokines. Using three healthy donors of different genetic backgrounds we compared Ig NGS data of PBMC repertoires with stimulated PBMC repertoires. In stimulated PBMCs we observed an enrichment of sequences of IgG subtypes and higher rates of SHM with no resulting bias in the representation of heavy or light chain variable domain families. We identified common V-D-J BCR sequences within one donor that persisted over three blood draws spanning a 9-month period, in PBMC and in stimulated PBMC Ig repertoires. The majority of the persistent BCR sequences identified in the stimulated repertoire, while fewer in number, showed \>1% SHM and isotype switching to IgG, consistent with being part of an antigen-experienced memory population. From the same donor, we cloned antigen-specific monoclonal antibodies (mAbs) from single memory B cells isolated by FACS with the hemagglutinin trimer of influenza A H1N1. Members of these mAbs clonal lineages were identified in PBMCs vs. stimulated PBMCs repertoires, quantified, and tracked over the three blood draws. An increased sensitivity for detection of individual mAbs along with larger, branching clonal families were obtained using data from stimulated PBMCs. Overall, our data support the application of stimulating PBMC samples to gain a deeper understanding of antigen-specific circulating memory B cell repertoires.

Materials and Methods {#s2}
=====================

Isolation of PBMCs
------------------

Leukapheresis was performed on three normal donors using Institutional Review Board (IRB)-approved consent forms and protocols by StemCell Technologies (Vancouver, BC). Approximately two to three blood volumes were processed using the Spectra Optia® Apheresis System to produce a full-sized Leuko Pak. Acid citrate dextrose, solution A (ACDA) was the anticoagulant. Donors included: 536, African American age 33, male, 82 kg, 180 cm, smoker, collected 11/15/2017, 5/24/2018, and 08/27/2018; 147, Caucasian female age 21, 56 kg, 153 cm, non-smoker, collected 08/21/2018; and 682, Hispanic male age 30, 74 kg, 181 cm, smoker, collected 08/16/2018. PBMCs were further enriched from the buffy coats of 50 ml tubes with 25 ml sterile Histopaque 1.077 (MilliporeSigma, Burlington, MA) layered with 25 ml leukocytes diluted 1:1 in PBS (no Ca^++^/Mg^++^), after centrifuging at 400 × g, 20°C, for 50 min (Eppendorf Centrifuge 5810, with swinging bucket rotor S-4-104, brake off). PBMCs from each 50 ml tube were washed by diluting three times with 50 ml ambient temperature RPMI 1640 and centrifuged 200 × g, 20°C, 10 min. PBMCs were cryopreserved in 90% heat-inactivated FBS, 10% DMSO at 1 × 10^7^ cells per vial.

Preparation of Growth-Arrested Feeder Cells
-------------------------------------------

Human fibroblast cell line MRC-5 (CCL-171) was obtained from ATCC® (Manassas, VA) and grown in B cell growth media containing Corning® DMEM \[+\] 4.5 g/L glucose, sodium pyruvate \[--\] L-glutamine (VWR International, Radnor, PA), 1xPen/Strep/Glu and 10% ultralow IgG HI-FBS (Thermo Fisher Scientific, Waltham, MA), to 80% confluence before being treated for 4 h with 5 μg/ml mitomycin C (Tocris, R&D Systems). Monolayers of growth arrested cells were washed 3 times with PBS, harvested with trypsin, neutralized with growth media, washed 1x in growth media and finally cryopreserved using 10% DMSO, 30% HI-FBS in growth media.

Preparation of PBMCs for BCR Repertoire Analysis
------------------------------------------------

PBMC vials were thawed rapidly in a 37°C water bath, immediately diluted into 10 ml of B cell growth media, and pelleted at 350 × g for 5 min. The sample was resuspended in growth media and B cells were negatively selected using the EasySep Human B cell Isolation Kit according to the manufacturer\'s protocol (STEMCELL Technologies, Vancouver, BC). Because our samples contained greater than one million PBMCs, B cell enrichment was used to provide a corresponding enrichment of B cell RNA in the total RNA added to the reverse transcription reaction. The final cells from negative enrichment were pelleted at 350 × g for 5 min, resuspended and lysed in Qiagen RLT buffer with beta-mercaptoethanol for 10 min, frozen on dry ice, and transferred to −80°C storage until RNA purification with the Qiagen AllPrep RNA/DNA kit (Qiagen, Hilden, Germany).

For generating stimulated PBMC samples, we applied methods previously published by McCutcheon et al. ([@B12]) to clone broadly neutralizing single B cells. The day before PBMCs were thawed, 1.2 × 10^6^ feeder cells were seeded in a T25 flask (VWR) in 4 ml of B cell growth media and cultured overnight in a humidified 37°C, 5% CO~2~ incubator. PBMCs were quickly thawed at 37°C, washed 1x in 10 ml of growth media, and resuspended in 4 ml of 2x B cell growth media containing 2 × ITS from 100x Insulin, Transferrin, Selenium (Thermo Fisher Scientific), 20 ng/ml IL-10, 2 ng/ml IL-2, 10 ng/ml IL-15, 10 ng/ml IL-6 (R&D Systems, Minneapolis, MN) and 4 μg/ml CpG (ODN 2006-G5, InvivoGen, San Diego, CA). The 4 ml of PBMCs were then added to the T25 flask with 4 ml of conditioned feeder cell media. The final 8 ml cell culture was allowed to grow for 5 days at 37°C, 5% CO~2~ in a humidified incubator. At day 5 the cells were pelleted at 350 × g for 5 min, resuspended and lysed in Qiagen RLT buffer with beta-mercaptoethanol for 10 min, frozen on dry ice, and transferred to −80°C storage until RNA purification. Since the culture conditions specifically expand memory B cells at the expense of viability of other cell types, no B cell enrichment was utilized at this step. Supernatants were also harvested to assay total IgG, IgA, and IgM secretion by indirect ELISA, as described below.

Indirect ELISA Measurement of Total IgG, IgA, and IgM
-----------------------------------------------------

96-well, Nunc Maxisorp™ plates (VWR, Radnor, PA) were coated overnight with anti-human IgG Fc (Jackson ImmunoResearch, West Grove, PA), anti-human IgA Fc or anti-human IgM Fc (Bethyl Labs, Montgomery, TX) at 2 μg/ml in PBS, pH7.2. The next day the plate was washed 3x 300 μl PBST and blocked for 1 h in 1% BSA/PBS. A standard curve was prepared using human reference serum (Bethyl Labs) in 1/3 dilutions starting from targeted serum dilutions to give 200 ng/ml of IgG, IgA, or IgM, in assay diluent (0.5% BSA//PBS/0.05% Tween-20). Supernatants from stimulated PBMCs were diluted in assay diluent between 1/5 and 1/100. Both standards and samples were allowed to bind for 2 h, washed 6x 300 μl PBST and a 1/5000 cocktail of anti-human kappa-HRP and lambda-HRP antibodies (SouthernBiotech, Birmingham, AL) added for 1 h in assay diluent. After 6x 300 μl PBST washes, the plate was developed with KPL SureBlue™ TMB (VWR).

BCR Primer Design and Pool Preparation
--------------------------------------

Dry oligos of desalted purity (IDT) were reconstituted at 100 μM in Qiagen EB and stored in aliquots at −80°C. The oligos are shown in [Table S1](#SM1){ref-type="supplementary-material"} and contain sufficient random base pairs to act as unique molecular identifiers (UMIs) for every mRNA transcript present in a sample. UMIs are added in variations of 8 or 12 nucleotide stretches to offset the high level of sequence similarity and lower Illumina sequencing accuracy in Ig amplicons at the 3′ and 5′ ends. A pool of IgH RT primers was made by mixing 10 μl of each primer from the individual 100 μM stocks (100 μl final volume). Separately 10 μl of each of lambda RT primers were mixed from individual 100 μM stocks (20 μl final volume). Next, a 10 μM, 5:1 molar mix of Ig heavy:lambda chain RT primers was made using 16.7 μl IgH RT primer pool and 3.3 μl lambda RT primer pool, in a final 180 μl of Qiagen EB. The same procedure and molar ratio were repeated in the preparation of the IgH (*n* = 12): lambda (*n* = 16) forward primers. Kappa RT and forward primer pools were prepared by mixing 10 μl of each kappa RT (*n* = 2) primer or kappa forward (*n* = 8) primer from the individual 100 μM stocks and then diluting the mix to 10 μM final.

BCR Amplicon Preparation
------------------------

Total RNA yields from the PBMC and stimulated PBMCs were in the range of 3 micrograms (50--100 ng/μl in 30 μl Qiagen EB buffer) determined by absorbance at 260 nm on the NanoDrop™ One (Thermo Fisher Scientific). An input of 100--200 ng total RNA was used for first strand cDNA synthesis with gene-specific reverse transcription (RT) primers directed to the constant regions. The RT primers for IgG, IgM, IgA, and lambda were pooled, whereas the kappa RT was done in a separate reaction. Light chain kappa RT was carried out in separate reactions because the transcript abundance and amplification efficiency tended to out-compete heavy and lambda chains in multiplexed reactions. Primers are shown in [Table S1](#SM1){ref-type="supplementary-material"}. One to two hundred nanograms total RNA was added on ice to 10 μM of pooled RT primers for HC/lambda or kappa chain (primer pools as described above and in [Table S1](#SM1){ref-type="supplementary-material"}) and 1 mM of dNTP in a 10 μl final volume, allowed to anneal for 3 min at 72°C, and returned to ice. First strand reverse transcription was performed using SuperScript III RT (200 U/μl, Thermo Fisher Scientific). To the 10 μl annealed sample, on ice, 4 μl of 5x Superscript RT buffer, 1 μl 0.1 M dithiothreitol, 1 μl Superase-IN (20 U/μl, Thermo Fisher), and 3 μl of RNase free water were added, to give a final volume of 20 μl. cDNA was made in a thermocycler for 1 h at 50°C, 5 min 85°C, 4°C hold. Second-strand cDNA was synthesized using Phusion High Fidelity Polymerase (Thermo Fisher). To the 20 μl first strand cDNA, 10 μl of 5X Phusion buffer, 1 μl of 10 mM dNTPs, 0.5 μl Phusion Taq, 1.5 μl DMSO, 7 μl of RNase free water, and 10 μl of the 10 μM pool of forward primers (as described above and shown in [Table S1](#SM1){ref-type="supplementary-material"}), were added, to give a final volume of 50 μl. Samples were incubated at 98°C for 4 min, 52°C for 1 min, 72°C for 5 min and 4°C hold. Double-stranded cDNA was transferred to a low retention DNase-free 1.5 ml Eppendorf tube and purified two times using Agencourt AMPure XP beads (Beckman Coulter, Brea, CA), at a volume ratio of 1:1, and eluted in 25 μl of Qiagen EB buffer. Double-stranded cDNA was PCR amplified with Platinum DNA Polymerase High Fidelity (5 U/μl HiFi Taq, Thermo Fisher). To the 25 μl of eluted 2nd strand cDNA, 5 μl of 10x HiFi Taq buffer, 2 μl of MgSO4, 1 μl 10 mM dNTPs, 0.2 μl HiFi Taq, 1 μl each of two PE primers completing Illumina adapter sequences ([Table S1](#SM1){ref-type="supplementary-material"}) and 14.8 μl of water, were added, to give a final volume of 50 μl. Samples were run at 94°C for 2 min, 27 cycles of 94°C for 30 s, 65°C for 30 s, and 68°C for 2 min, followed by 68°C for 7 min and 4°C hold. Final libraries were run on 2% E-Gel EX agarose gels (Thermo Fisher Scientific) and bands extracted with Quantum Prep Freeze and Squeeze DNA Extraction Spin Columns (BioRad, Hercules, CA). After one clean-up with 1:1 Agencourt AMPure XP beads, amplicons were eluted in 25--35 μl Qiagen EB. An aliquot was diluted to 5--500 pg/μl and 2 μl quantified on the Agilent Fragment Analyzer Automated CE System using the DNF-474 High Sensitivity, 1--6,000 bp, NGS Fragment Analysis Kit (Advanced Analytical Technologies, Agilent Technologies, Santa Clara, CA), according to the manufacturer\'s instructions. Pairs of samples (PBMC and stimulated PBMC amplicons) were sequenced together using different Illumina barcodes to demultiplex after sequencing. Amplicon mixtures corresponding to 10:1 ratios of heavy chain + lambda: kappa were submitted for 300 forward × 250 reverse sequencing with MiSeq v3 kits (Illumina) at the Chan Zuckerberg Biohub Genomics Center. Addition of 15--20% PhiX was added to increase sequence diversity and overall sequencing performance. Each MiSeq run resulted in 7.5--20 million paired raw reads, which was reduced to 0.5--3.5 million unique Ig sequences after processing. All MiSeq data is deposited in the SRA database under accession PRJNA524904.

BCR Repertoire Data Analysis Pipeline
-------------------------------------

After completion of MiSeq sequencing, antibody repertoires were analyzed using methods based on the Immcantation pipeline ([@B13], [@B14]). An overview of BCR sequencing analysis and practical considerations included in the Immcantation pipeline, are reviewed in Yaari and Kleinstein ([@B15]). This pipeline continues to be updated as the field advances, and is composed of multiple software packages: pRESTO, Change-O, SHazaM, TIgGER, and Alakazam, found at <https://immcantation.readthedocs.io>. Because the Immcantation pipeline can be run using Docker containers, we created a cloud-based workflow incorporating Reflow (<https://github.com/grailbio/reflow>) that allowed for seamless processing of the constituent Immcantation software packages. The workflow is available at Github (<https://github.com/czbiohub/bcell_pipeline>). Some key characteristics of our workflow include the use of unique molecular identifiers \[UMIs; ([@B16], [@B17])\] at both 5′ and 3′ ends of the Ig sequences, the collapse of sequences with identical UMIs, the use of the IgBLAST algorithm ([@B18]) to calculate general Ig characteristics of each sequence, and the determination of clonal families by first calculating a clonal threshold nucleotide distance via a nearest-neighbor algorithm and then collapsing sequences based on this threshold ([@B9]). We ran the initial steps using the pRESTO script (presto-abseq.sh at <https://bitbucket.org/kleinstein/immcantation/src/97a70949607b6671a182a84d5052b705d1677891/pipelines/?at=default>) with variations that are included in our Github repository. Given that our sample and amplicon preparation included UMIs of varying lengths at both 5′ and 3′ ends to improve sequencing quality, we included code to standardize the UMI length for subsequent steps (8 bp at each end). The script first removes reads with average Q scores \>20, and then annotates the reads based on 5′ or 3′ amplicon primers. All reads with identical UMIs are then collapsed, with consensus sequences created and UMI numbers annotated into the sequence name. This is followed by assembly of 5′ and 3′ paired-ends, at which point the UMIs at both ends are combined to create a 16 bp signature per cDNA transcript, also annotated into the sequence name. In the next step, the constant regions are re-analyzed for each paired read, and isotype and subtype annotated into the sequence name. The final pRESTO steps include collapsing of identical BCR sequences of the same isotype followed by filtering to only include BCR sequences that were found in 2 or more representative reads per UMI, to avoid including sequences that vary only due to sequencing error. The workflow continues with subsequent Immcantation packages, using the following scripts without changes at the website above: Change-O IgBLAST (changeo-igblast.sh), which calculates Ig repertoire characteristics, TigGER (tigger-genotype.R), which estimates novel V-gene alleles, SHazaM (shazam-threshold.R), which determines the optimal threshold for delineating clonal families, and Change-O Clone (changeo-clone.sh) that groups the sequences into clonal families. Lastly, we use a series of R scripts based on Alakazam that can be found at our Github page to visualize results. This workflow includes both heavy and light chain reads, and all outputs include both sequences, but without knowledge of pairing, therefore we have focused only on the more diverse heavy chain results. In addition to the Immcantation procedure of optimizing the clonal threshold value during each analysis (using SHazaM), we used a second strategy for comparisons across samples to identify mAb matches to clonal families in the repertoire. For these comparisons, we extracted all unique heavy chain sequences (i.e., not only those with 2 or more reads per UMI), appended the mAb sequences, and applied a constant 12% threshold value in Change-O to delineate clonal families. This 12% value was derived using the median of all individual optimized threshold values determined from the multiplexed heavy and light chain data. The Change-O method requires identical V-gene and J-gene usage, CDRH3 length, and in this case up to 12% nucleotide mismatch in the CDRH3 was allowed.

Preparation of Samples for Bulk Transcriptome Analysis
------------------------------------------------------

Double stranded cDNA was prepared according to the single B cell cDNA synthesis described below. cDNA was diluted to range of 0.1--0.3 ng/μl, before tagmentation and PCR amplification with index primers using the Nextera XT DNA SMP Prep Kit and Nextera XT IDX Kit (Illumina, San Diego, CA). After cleanup with Agencourt AMPure XP beads (Beckman Coulter, Brea, CA) the sample was eluted in Qiagen EB buffer and quantified on the Agilent Fragment Analyzer Automated CE System using the DNF-474 High Sensitivity, 1--6,000 bp, NGS Fragment Analysis Kit (Advanced Analytical Technologies, Agilent Technologies, Santa Clara, CA), according to the manufacturer\'s instructions. Libraries were submitted for 75 × 75 bp sequencing on the Illumina NextSeq High Output instrument. Raw transcriptomic data is deposited in the SRA database under accession PRJNA526542.

Single Memory B Cell Isolation
------------------------------

Human PBMCs were thawed and stained for 1 h on ice in PBS, 1% BSA (w/v) with antibodies for positive markers of IgG memory B cells, and antibodies to negatively select and avoid contamination with dead cells, T cells, NK cells or monocytes (live, CD3^−^,CD14^−^,CD56^−^, IgM^−^, IgA^−^, CD19^+^,CD20^+^,CD27^+^). Biotinylated HA trimer (A/New Caledonia/20/1999) was complexed using 50 nM at a 4:1 molar ratio with Streptavidin. HA was produced in-house by transiently transfecting Expi293 cells with the extracellular region of HA containing a C-terminal foldon domain for trimerization ([@B19]), Avi-tag for biotinylation and 6xHIS tag for Nickel purification using the HisPur™ Ni-NTA Spin Purification Kit (Thermo Fisher Scientific, Waltham, MA). Specific antibody clones and labels are listed in [Table S2](#SM1){ref-type="supplementary-material"}. The SH800 Cell Sorter was used with 100 μm sorting chips (SONY Biotechnology, San Jose, CA) and NERL™ Diluent 2/Sheath Fluid for Flow Cytometry (Thermo Fisher). Laser compensation was performed using the AbC™ Total Antibody Compensation Bead Kit (Thermo Fisher). Single cells were sorted directly into Hard-Shell® 96-well, low profile, thin wall, skirted, green/clear, PCR plates (BioRad) with 4 μl of lysis buffer, frozen immediately on dry ice and stored at −80°C. cDNA was synthesized according to published Smart-seq2 methods ([@B20]). cDNA was cleaned up using 18 μl of Agencourt AMPure XP beads (Beckman Coulter, Brea, CA) in the 25 μl final cDNA volume, washed twice with 170 μl 80% ethanol and eluted in 16 μl of Qiagen EB. Heavy and light chain variable domains were amplified (95°C 5 min, 30 cycles: 95°C 15s, 57°C 30 s, 68°C 1 min; and a final 10 min 68°C extension) from 2 to 3 μl of cDNA in 25 μl of Accuprime Pfx supermix (Invitrogen, Thermo Fisher Scientific) and 0.5 μl of the VH, VK, or VL primer stock mixes described in [Table S3](#SM1){ref-type="supplementary-material"}. Sanger sequencing primers are also listed in [Table S3](#SM1){ref-type="supplementary-material"}.

Recombinant Antibody Cloning, Production, and Purification
----------------------------------------------------------

Variable heavy or light chain domain PCR products were re-amplified in a nested PCR using primers with at least a 15 base pair overlap matching the 5′ signal sequence and 3′constant region of our human IgG~1~, kappa or lambda expression vectors (see [Table S3](#SM1){ref-type="supplementary-material"} for primers). MEDI8852 was made in-house using geneblocks (IDT) corresponding to the published sequence ([@B21]). Expression vectors used were in-house constructs of Genbank LT615368.1, deposited by Tiller et al. ([@B22]). Assembly of the gene fragments into expression vectors was performed with In-Fusion HD Cloning (Takara Bio USA, Mountain View, CA) and confirmed by Sanger sequencing (Sequetech, Mountain View, CA). Miniprep DNA (5 μg) for the HC and LC of each mAb was transfected into 5 ml of suspension Expi293 cells according to the manufacturer\'s instructions (Thermo Fisher Scientific) in 50 ml tubes. Cultures were grown in a Multitron shaker (INFORS HT, Annapolis Junction, MD) for 5 to 8 days before supernatants were harvested, clarified, purified and assayed for HA binding. Antibodies were batch purified by adding 500 μl of 1:1 slurry of MabSelect™ SuRe™ (GE, Chicago, IL) overnight. Supernatants and beads were decanted and rinsed into 10 ml Poly-Prep® Chromatography Columns (BioRad, Hercules, CA), washed with 20 volumes of PBS and eluted in 5 ml of 20 mM citrate buffer, pH3, neutralized with 250 μl of 75 mM 1.5 M Tris-HCl, pH8.8. Purified antibodies were concentrated and exchanged by centrifugation into PBS, pH7.2 using Amicon Ultra-15 Centrifugal Filter Units with Ultracel-10 membranes (MilliporeSigma, Burlington, MA). IgG concentrations were determined by OD280 on the Nanodrop One.

ELISA Measurement of mAb Binding to HA
--------------------------------------

96-well, Nunc Maxisorp™ plates were coated overnight with 1 μg/ml H1N1 A/New Caledonia/20/1999 hemagglutinin (HA) trimer in PBS, pH7.2. The coated plates were washed 3x 300 μl PBST and blocked for 1 h in 1% BSA/PBS before adding a 1/3 titration of mAbs in assay diluent (0.5% BSA/PBS/0.05% Tween-20) for 1 h at ambient temperature. Plates were washed 6x 300 μl PBST and developed with secondary antibodies and TMB as described above. To measure the binding of mAbs in the presence of MEDI8852 Fab, the MEDI8852 IgG was cut to severe all Fc with LYSYL endopeptidase (Wako Chemicals, Richmond, VA) for 2 h at 37°C. Plates were coated and blocked as described in the binding assay. Each mAb was prepared at a fixed concentration in 0.5% BSA/PBS/0.05% Tween-20 corresponding to a binding OD of 2. A 1/3 dilution series of MEDI8852 Fab was prepared starting from 100 nM. Each mAb was added 1:1 to the Fab dilution series and allowed to bind for 1 h at ambient temperature. Plates were washed 6x 300 μl PBST and developed with an anti-human Fc specific secondary antibody (Invitrogen, Carlsbad, CA) and TMB as described above. Control wells for Fab binding alone were assayed alongside and the final signal subtracted from each corresponding dilution.

Results {#s3}
=======

Experimental Rationale of PBMC BCR Repertoires +/-- Stimulation
---------------------------------------------------------------

PBMCs from three normal donors of different genetic backgrounds 536 (African American male, 33 yrs), 147 (Caucasian female, 21 yrs.), and 682 (Hispanic male, 30 yrs.) were purified and cryopreserved from Leukapheresis packs. Blood from donor 536 was collected at three different times, in November 2017, May 2018, and August 2018, while donors 147 and 682 were collected once, in August 2018. PBMC vials of 10^7^ cells were processed in one of four ways to obtain (i) PBMC B cell repertoires; (ii) stimulated PBMC B cell repertoires; (iii) bulk transcriptome profiles; or (iv) single, antigen-specific memory B cells. Two vials of cells were processed for each repertoire condition for each of the three donors, in separate experiments, to replicate data. Examples of typical BCR amplicon products used for NGS, which looked similar between PBMC and stimulated PBMC, are shown in [Supplementary Image S1](#SM2){ref-type="supplementary-material"}. The analysis of Ig repertoires from NGS data is described in detail in the Methods section and a summary of the workflow is provided in [Figure 1](#F1){ref-type="fig"}. Our PBMC stimulation was based on methods previously demonstrated to give rise to the selective expansion, identification, and cloning of antigen-specific memory B cells ([@B12]). This method was found to provide the most NGS sequence depth and diversity compared to the alternative approaches of isolating total memory B cells from PBMC by FACS for NGS sequencing or using selective amplification of IgG mRNA from PBMC enriched B cells ([Supplementary Image S2](#SM3){ref-type="supplementary-material"}). Total IgG, IgM, and IgA secreted by activated B cells was measured between 82 and 954, 29 and 266, and 8 and 35 ng/ml among replicate stimulated cultures of the three donors, respectively ([Table 1](#T1){ref-type="table"}). These donors\' recent infection or vaccination history is not known, but could be reflected in the observed variability of the numbers. For instance, donor 536 may have had a recent exposure at the November timepoint resulting in higher measured IgG and IgM levels relative to other timepoints and donors. The functional *in vitro* stimulation of the PBMCs was further characterized by mRNA expression. Total RNA was used to compare the bulk cellular transcriptome in one replicate of each of the three donors PBMCs before and after stimulation. Upon stimulation, transcripts corresponding to both innate and adaptive immunity were upregulated 10- to 1000-fold over unstimulated PBMCs. Representative genes for T cell and T cell Receptor (TCR) activation, BCR activation and B cell differentiation, as well as genes involved in various innate immune cell activities are shown in [Table 2](#T2){ref-type="table"}. The stimulation of PBMCs to increase representation of memory B cells should correspond to an improved ability to identify monoclonal antibody sequences in NGS repertoires. However, once a memory B cell is stimulated it loses the transcriptional and cell surface markers of memory and antigen specificity and cannot be identified in a PBMC mixture. Therefore, to test the hypothesis, eight antigen-specific mAbs to the hemagglutinin trimer of influenza H1N1 were obtained by FACS from one donor (536, November blood draw sample), the heavy and light chains sequenced from single cells, and recombinant mAbs made. Their binding activity was confirmed by ELISA using the H1N1 trimer, to which no non-specific IgG binding was observed (data not shown). The mAbs, derived from several different IGVH germlines, demonstrated ELISA binding EC~50~ values in the range of 3--40 nM ([Figure 2A](#F2){ref-type="fig"}), comparable to the high affinity, highly cross-reactive, MEDI8852 mAb directed to the HA stalk region ([@B21]). The binding of antibodies INF3, INF7, INF9, and INF11 to the HA trimer demonstrated dose-dependent blocking by the Fab fragment of MEDI8852 (Fab blocking the intact MEDI8852 mAb is shown in black), indicative of common binding to the HA stalk region ([Figure 2B](#F2){ref-type="fig"}). At high Fab concentrations most mAbs reached a plateau level of binding, including the IgG form of MEDI8852. This likely reflects a steady state level of Fab displacement by IgG binding with higher affinity and avidity during the 1 h incubation time. Alternately, some mAbs may be able to retain a low level of equilibrium binding to partial epitopes outside the stalk region. Data identifying these memory B cell mAbs in the repertoires of donor 536 is reported below.

![Schematic of the BCR analysis workflow. Raw paired MiSeq reads (300 × 250 bp) are inputted into the Immcantation pipeline. The pRESTO package processes the MiSeq reads and does QC, UMI processing, primer and isotype/subtype annotation and paired read assembly to output annotated sequence lists (.fastq). Change-O next runs the IgBLAST algorithm on all processed Ig sequences, annotating germline information to output tabular files (.tab). TigGER calculates novel germlines, while SHazaM calculates the optimal threshold for clonal clustering. Change-O then clusters the sequences into clones and Alakazam summarizes the outputs in graphical form (.png &.pdf). Throughout the workflow, a Reflow script pieces all of the parts together, delineating outputs and inputs and allowing the pipeline to run in the cloud (using Amazon Web Services).](fimmu-10-01452-g0001){#F1}

###### 

Immunoglobulin in leukopak supernatant and secreted from stimulated PBMC cultures.

                **Leukopak supernatant μg/mL**   **5-day B cell stimulated media ng/mL**                                             
  ------------- -------------------------------- ----------------------------------------- ----- ----- ----- ----- ----- ----- ----- -----
  IgG           192                              129                                       121   138   190   448   329   278   185   417
  (replicate)   --                               --                                        --    --    --    954   374   82    123   362
  IgM           483                              296                                       273   212   240   163   96    57    29    57
  (replicate)   --                               --                                        --    --    --    266   97    45    34    55
  IgA           22                               11                                        14    15    25    24    19    13    8     13
  (replicate)   --                               --                                        --    --    --    35    14    11    9     11

*N, November; M, May; A, August*.

###### 

RNAseq TPM for innate and adaptive immune responses observed between PBMCs and *in vitro* stimulated PBMCs^[a](#TN2-1){ref-type="table-fn"},[b](#TN2-2){ref-type="table-fn"}^.

                          **Donor 147**   **Donor 536**   **Donor 682**                   
  ----------------------- --------------- --------------- --------------- ------- ------- -------
  **IMMUNE CELL GENES**                                                                   
  C1QC                    11              1665            3               210     5       275
  CCL2                    66              11270           41              4201    107     3650
  CCR2                    25              131             15              94      16      240
  CCR5                    16              149             1               152     11      100
  CD209                   22              206             5               51      3       48
  CD96                    112             759             155             864     99      457
  CXCL1                   6               1332            3               945     10      327
  CXCL8                   100             5120            6               5297    2115    679
  FCGR1A                  5               77              1               17      11      23
  GNLY                    173             16725           61              34281   1145    15864
  GZMB                    50              9929            22              23228   138     13583
  IL7R                    29              620             18              265     106     523
  LAG3                    11              220             14              259     5       287
  LEF1                    28              640             20              318     84      336
  PRF1                    13              2422            16              3739    66      1525
  RSAD2                   27              130             7               82      6       34
  SLA2                    27              480             19              511     119     334
  SLAMF7                  61              629             79              801     92      297
  XBP1                    750             4768            997             9573    1899    9564
  XCL2                    67              288             45              592     14      314
  ZAP70                   125             1891            45              1624    418     1392
  KLF2                    3845            379             5462            171     3050    467
  DUSP1                   10458           88              23692           86      16369   84
  FOS                     4733            73              16289           28      15844   33
  BLK                     2239            96              1822            45      1499    106
  MALAT1                  93664           8407            54234           2502    30961   3405
  **T CELL GENES**                                                                        
  CD247                   18              302             11              1262    41      241
  CD274                   10              1180            11              88      112     628
  CD3D                    44              3023            23              1675    465     2064
  CD3E                    43              1431            9               1315    322     931
  CD3G                    10              1979            15              269     33      1496
  CD7                     24              3960            10              723     120     1723
  CD8A                    14              435             9               1337    132     463
  CD8B                    14              531             20              1674    87      576
  CISH                    37              688             23              2026    120     443
  EOMES                   25              886             9               305     139     536
  HAVCR2                  74              1271            12              760     93      917
  LAT                     33              761             27              1725    62      417
  PRKCQ                   46              365             18              350     44      250
  SIT1                    52              224             44              523     17      207
  SPN                     12              91              9               421     13      72
  TRAT1                   46              513             2               280     35      244
  TXK                     13              191             15              208     16      214
  ZNF683                  60              407             11              211     27      159
  CD69                    2785            472             4815            336     3263    319
  **B CELL GENES**                                                                        
  CD27                    145             1199            154             1363    93      1249
  CD38                    14              141             23              218     4       117
  IGLL5                   2465            8230            2102            21659   896     25995
  JCHAIN                  461             1945            737             7780    252     9099
  PRDM1                   37              198             47              383     67      254
  UNG                     21              250             8               260     6       191
  CD22                    941             101             1854            99      572     136
  CR2                     33              4               30              7       11      3
  CD79A                   14254           1520            12293           1980    9219    4541
  LYN                     923             185             1290            125     780     153

*August timepoint; Most highly upregulated genes from Adaptive Immune Response GO_0002250*.

*TPM = reads (mapped to only one gene) normalized for gene length and then normalized for sequencing depth*.

![ELISA binding of mAbs to H1N1 HA and functional epitope mapping to the stalk region. **(A)** Purified recombinant monoclonal antibodies were tested for binding to the H1N1 HA trimer compared to the reference in house synthesized MEDI8852 IgG (shown in dotted black line). Replicate data is plotted as a percentage of the maximum in-assay OD~450~ signal which was saturated at 50 nM for all IgG. **(B)** The binding of monoclonal antibodies was measured after blocking the coated HA trimer with increasing concentrations of MEDI8852 Fab. The binding of antibodies INF3, INF7, INF9, and INF11 to the HA trimer were effectively blocked by the Fab fragment of MEDI8852 (Fab blocking the intact MEDI8852 mAb itself is shown in the dotted black line), indicative of common binding of these mAbs to the HA stalk region. In this assay, only INF11 was close to completely blocked at high Fab concentrations. During the 1 h incubation time, higher avidity and affinity IgG (including MEDI8852 IgG) may have reached an equilibrium by displacing bound Fab or by binding to partial epitopes on the trimer independent of the stalk region.](fimmu-10-01452-g0002){#F2}

Equivalent Germline Usage in PBMC and Stimulated PBMC Repertoires
-----------------------------------------------------------------

We examined PBMC and stimulated PBMC repertoires using our workflow based on the Immcantation pipeline, using an optimized clonal threshold value for each sample and limiting data to sequences with at least 2 representative reads per UMI. Comparing V-gene usage between replicate repertoires, we found that in both PBMC and stimulated PBMC repertoires gene usage was consistent with previously described healthy BCR repertoire data ([@B23]), and germline usage was equivalent across PBMC and stimulated PBMC repertoires (e.g., VH in [Figure 3](#F3){ref-type="fig"}, and VK/VL in [Supplementary Image S3](#SM4){ref-type="supplementary-material"}). For example, examining IgG and IgM sequences in one replicate at one timepoint, VH1-2, VH3-23, VH3-33, VH4-59, and VH5-51 are among the most commonly used V-genes across both PBMC and stimulated PBMC repertoires in donor 147, VH1-2, VH1-69, VH3-30, VH4-39, and VH5-51 are among the most commonly used V-genes across both PBMC and stimulated PBMC repertoires in donor 536, and VH1-69, VH3-23, VH4-39, VH4-59, and VH5-51 the most commonly used V-genes across both PBMC and stimulated PBMC repertoires in donor 682. The largest differences in gene usage between PBMC and stimulated PBMC repertoires occur in the most commonly used antigen-specific V-genes, particularly VH1-69, VH4-39, and VH4-59.

![Germline V-gene usage among PBMC and Stimulated PBMC repertoires. Plots show V-gene usage for one replicate of each of the three donor repertoires (**A**: 147, **B**: 536, and **C**: 682) sampled at the August 2018 timepoint, and are separated by isotype, with only IgM and IgG sequences shown. Plots were made using the Alakazam R scripts in the Immcantation pipeline. Corresponding V-gene usage plots for light chains are in [Supplementary Image S3](#SM4){ref-type="supplementary-material"}.](fimmu-10-01452-g0003){#F3}

Stimulated PBMC Repertoires Shift to More Antigen-Experienced Sequences
-----------------------------------------------------------------------

We examined whether PBMC and stimulated PBMC repertoires vary in their antigen experience by quantifying heavy chain isotype ratios and SHM among IgM and IgG sequences. To more accurately calculate SHM, we used the Immcantation package TigGER which includes inferred novel alleles in downstream SHM calculations. TigGER found between 3 and 11 novel alleles per donor (refer to [Table S4](#SM1){ref-type="supplementary-material"}). Among replicate samples of three donors, we found a consistent shift in repertoires with respect to the proportions of heavy chain isotype and subtype content. In PBMC repertoires, IgM made up over 90% of all heavy chain sequences across all samples and replicates. In contrast, stimulated PBMCs are greatly enriched for IgG and particularly the IgG~1~ subtype, comprising between 58 and 82% of all heavy chain sequences ([Figure 4](#F4){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). Somatic hypermutation frequencies ([Figure 5](#F5){ref-type="fig"}) also significantly increased in the 3 different donors, although to varying degrees (Student\'s *t*-tests with Holm-Sidak correction, yielded *p* \< 0.001 values for all comparisons). Variations in SHM may reflect the donors exposure history and immune status at the time of the blood draw. PBMC repertoires averaged 0.7% SHM in IgM sequences and 5.1% SHM in IgG sequences ([Table 3A](#T3){ref-type="table"}), while stimulated PBMC repertoires averaged 2.2% SHM in IgM sequences and 6.0% SHM in IgG sequences ([Table 3B](#T4){ref-type="table"}).

![Heavy chain isotype and subtype usage among PBMC and stimulated PBMC repertoires. Plots show the proportion of heavy chain isotypes for one replicate of each of the three donors (147, 536, and 682) sampled at the August 2018 timepoint. While pie chart numbers show unique Ig sequences found with \>2 reads per UMI, the more stringent criteria for enumerating clonal families by V-D-J sequence similarity is also shown (in bold numbers on pie charts). A constant clonal threshold value of 12% was used to assign sequences into clonal families, so data could be compared across samples (see Methods). Plots were made using the Alakazam R scripts in the Immcantation pipeline.](fimmu-10-01452-g0004){#F4}

![Somatic hypermutation among PBMC and stimulated PBMC repertoires. Plots show distributions of SHM values across all IgM and IgG sequences in PBMC repertoires vs. stimulated PBMC repertoires in one replicate, for each of the three donors (147, 536, and 682) sampled at the August 2018 timepoint. Plots were made using the Alakazam R scripts in the Immcantation pipeline. Since the total number of sequences in each distribution plot are different, to compare across samples, the y-axis were normalized to the maximum number of sequences.](fimmu-10-01452-g0005){#F5}

###### 

Summary of Ig sequences^[a](#TN3-1){ref-type="table-fn"}^, clonal families, and their corresponding mean SHM in two experimental replicates of PBMCs.

  **PBMCs^[b](#TN3-2){ref-type="table-fn"}^**                        **147A**   **536N**   **536M**   **536A**   **682A**                                          
  ------------------------------------------------------------------ ---------- ---------- ---------- ---------- ---------- --------- --------- -------- --------- --------
  HC sequences                                                       90398      59651      112128     144519     139389     186664    253586    173944   239491    145578
  HC clonal families                                                 75672      49595      95095      102093     119668     148994    204129    145749   202146    129432
  IgM sequences                                                      82607      53839      103577     132636     129498     174385    238019    163658   217268    131032
  SHM, IgM sequences                                                 0.8%       0.8%       0.8%       1.0%       0.8%       0.8%      0.6%      0.6%     0.6%      0.5%
  IgG sequences                                                      4768       3255       4760       7174       5481       7135      8735      6389     12916     7566
  SHM, IgG sequences                                                 4.4%       4.3%       5.5%       5.4%       5.5%       5.4%      5.4%      5.4%     5.1%      5.1%
  IgA sequences                                                      3023       2557       3791       4709       4410       5144      6825      3897     9307      6980
  SHM, IgA sequences                                                 4.6%       4.6%       4.8%       4.9%       4.9%       4.8%      4.9%      4.8%     5.6%      5.4%
  Unique clonal family threshold^[c](#TN3-3){ref-type="table-fn"}^   12.8%      15.0%      9.7%       18.0%      9.2%       10.9%     8.5%      8.2%     6.0%      8.0%
  IgM clonal families                                                68789      44406      87385      92265      110789     138560    190087    136855   183286    117115
  SHM, IgM clonal families                                           0.6%       0.6%       0.6%       0.6%       0.6%       0.5%      0.4%      0.4%     0.5%      0.5%
  IgG clonal families                                                4231       2935       4277       5815       4900       6000      7286      5427     11505     6637
  SHM, IgG clonal families                                           4.3%       4.2%       5.3%       5.1%       5.5%       5.2%      5.3%      5.3%     5.1%      5.0%
  IgA clonal families                                                2652       2254       3433       4013       3979       4434      5798      3467     7355      5680
  SHM, IgA clonal families                                           4.5%       4.5%       4.7%       4.6%       4.8%       4.7%      4.8%      4.8%     5.4%      5.4%
  HC all unique reads                                                512326     305131     518555     978166     641993     1036751   1116641   965622   1167074   836912
  IgM clonal families, 12%^[d](#TN3-4){ref-type="table-fn"}^         123144     84103      155977     191438     160517     212548    275685    191826   278478    178061
  IgG clonal families, 12%                                           6943       4458       7411       11093      6926       10129     11354     8279     14739     9021
  IgA clonal families, 12%                                           4052       3560       6143       7719       5861       7724      9392      5597     8524      7586

*sequences with reads per UMI ≥ 2*.

*N, November 2017; M, May 2018; A, August 2018*.

*redundant and variable amounts of amplified light chains multiplexed with the heavy chains for sequencing contributed to variability in these numbers*.

*12% = secondary clonal threshold based on 12% distance, using all unique reads*.

###### 

Summary of Ig sequences^[a](#TN4-1){ref-type="table-fn"}^, clonal families and their corresponding mean SHM in two experimental replicates of *in vitro* stimulated PBMCs.

  **Stimulated PBMCs^[b](#TN4-2){ref-type="table-fn"}^**             **147A**   **536N**   **536M**   **536A**   **682A**                                        
  ------------------------------------------------------------------ ---------- ---------- ---------- ---------- ---------- -------- -------- -------- --------- ---------
  HC sequences                                                       128312     99898      71594      124013     185986     179813   51720    142435   58893     89055
  HC clonal families                                                 72805      41404      12626      19424      64264      86379    15838    51756    21798     26944
  IgM sequences                                                      69335      34993      13295      28893      64401      85831    6039     54147    2430      13437
  SHM, IgM sequences                                                 1.2%       1.1%       4.2%       2.8%       1.8%       1.3%     4.0%     1.2%     3.4%      1.4%
  IgG sequences                                                      55161      62984      55233      89078      113665     87748    44577    84324    56846     73874
  SHM, IgG sequences                                                 4.7%       4.5%       6.4%       6.5%       6.3%       6.1%     6.6%     6.7%     5.8%      6.2%
  IgA sequences                                                      3816       1921       3066       6042       7890       6234     1104     3964     606       1744
  SHM, IgA sequences                                                 4.9%       4.7%       6.1%       5.9%       5.8%       5.7%     5.9%     5.8%     6.3%      6.3%
  Unique clonal family threshold^[c](#TN4-3){ref-type="table-fn"}^   13.6%      12.0%      19.0%      18.0%      8.4%       11.5%    19.3%    8.6%     20.2%     12.9%
  IgM clonal families                                                52584      27928      3267       12249      42532      63103    2034     38535    1258      10068
  SHM, IgM clonal families                                           0.7%       0.7%       1.5%       0.8%       0.7%       0.6%     1.9%     0.5%     2.1%      0.7%
  IgG clonal families                                                17331      12179      8557       5896       18706      19822    13321    11631    20438     15465
  SHM, IgG clonal families                                           4.6%       4.6%       6.0%       6.1%       6.2%       6.1%     6.0%     6.5%     5.5%      5.8%
  IgA clonal families                                                2620       1297       802        1279       3026       3454     483      1590     377       791
  SHM, IgA clonal families                                           4.7%       4.8%       6.1%       5.6%       5.5%       5.4%     6.2%     5.6%     6.1%      6.0%
  HC all unique reads                                                1071506    689021     768278     875935     1564721    953708   627655   971885   1103074   1046912
  IgM clonal families, 12%^[d](#TN4-4){ref-type="table-fn"}^         78685      39000      23783      19200      36281      80939    17171    54315    19747     54699
  IgG clonal families, 12%                                           41078      30372      26472      18338      46555      39857    33954    28099    65559     42795
  IgA clonal families, 12%                                           3523       1814       3792       3472       8451       6632     1299     3675     1541      2462

*sequences with reads per UMI ≥ 2*.

*N, November 2017; M, May 2018; A, August 2018*.

*redundant and variable amounts of amplified light chains multiplexed with the heavy chains for sequencing contributed to variability in these numbers*.

*12% = secondary clonal threshold based on 12% distance, using all unique reads*.

Increased Sensitivity for Detection of Antigen-Specific mAbs From Stimulated PBMC Repertoires
---------------------------------------------------------------------------------------------

In order to identify and quantitatively compare single cell mAb matches to clonal families among different repertoire samples from a given donor, we included all unique heavy chain sequences, appended the focal mAb sequences, and applied a constant 12% clonal threshold nucleotide distance during analysis. By using a constant clonal threshold value to apply across sample replicates and timepoints rather than allowing the threshold to be a variable, we thus provide a consistent delineation between sequence relationships in the datasets being compared. In our searches for single cell memory mAbs in donor 536, we found matching clonal families for the influenza mAbs most frequently among stimulated PBMC repertoires across all blood draw timepoints ([Figure 6A](#F6){ref-type="fig"}). These hit rates improved despite the fact that the total number of clonal families in stimulated PBMC repertoires were up to 12-fold lower than PBMC (e.g., 204,129 vs. 15,838 in a single August replicate for donor 536; [Tables 3A,B](#T3){ref-type="table"}), because sequences were enriched for the IgG switched and higher SHM phenotype of antigen-experienced BCR ([Figures 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}). As would be expected from analyzing samples from a dynamic immune system, we observed differences in mAb matches to Ig repertoires among the timepoints. As shown in [Figure 6A](#F6){ref-type="fig"}, mAb searches at the initial timepoint (November), when the mAb B cells were isolated, showed equal hits for PBMC and stimulated PBMC (4/8 mAbs). The second timepoint (May) had the greatest number of matches in the stimulated PBMC repertoire (7/8 mAbs), relative to the PBMC (2/8), while the number at the third timepoint (August) dropped to 0/8 mAbs in PBMC and 2/8 mAbs in stimulated PBMC. The donor was collected as healthy and no medical history is known, but these findings could be consistent with this donor having received exposure or vaccination to influenza A virus just prior to the November blood draw, reducing the sampled diversity during selective clonal expansion, with the immune response waning in the PBMC compartment by the following August. It is also possible that this donor experienced additional exposures to Influenza A between the November and May blood draws, further reinforcing memory clones. In addition to identifying mAb clonal families in the stimulated PBMC repertoires more frequently, we also found considerably more sequences matching these clonal families ([Figure 6B](#F6){ref-type="fig"}). Out of 5 million total processed Ig sequences with unique UMI across PBMC repertoires for November, May and August, sequences matching the mAb clonal families ranged from 0 to 18, while in stimulated PBMC repertoires, matching mAb sequences ranged from 95 to 448 out of a total of 7 million processed Ig sequences. Activated B cells proliferate and significantly upregulate mRNA transcription, thus making clonal families of interest more easily found, and found in larger numbers. Further analyses of the relative size and diversity of the mAb clonal families at the May timepoint, are described in sections below.

![Clonal families of 8 HA^+^ memory B cell sequences found among PBMC and stimulated PBMC repertoires. **(A)** Number of mAbs out of the eight HA^+^ memory B cell sequences found with clonal families in either PBMC repertoires or stimulated PBMC repertoires, for all three timepoints of donor 536. One mAb (INF15) was not found in any of the repertoires. **(B)** Number of sequences found within these clonal families, in either PBMC repertoires or stimulated PBMC repertoires for all three timepoints of donor 536.](fimmu-10-01452-g0006){#F6}

Persistent BCR Sequences With Antigen Experience Are Found More Frequently in Stimulated PBMC Repertoires
---------------------------------------------------------------------------------------------------------

With the three samples of PBMCs drawn from a single donor, we examined whether there were "persistent" BCR sequences found across all timepoints spanning a 9 month period, continuing with the strategy including all unique heavy chain sequences and applying a constant 12% clonal threshold. Identical BCR sequences found consistently over time would more likely be derived from the memory B cell population, particularly if they have switched to the IgG isotype and have V-D-J sequences mutated from germline. Searches for identical BCR sequences were conducted in Geneious v11.1 (Biomatters, Auckland, New Zealand) on data merged from the replicate experiments, using DNA segments corresponding to FR1 residue 12 to FR4 residue 136 (Kabat numbering). Among 5 million processed Ig sequences from donor 536 PBMC across November, May and August, we found 7229 BCR sequences identical at the nucleotide level that persisted across all timepoints, of which only a small fraction (173) were mutated IgG BCR sequences. In contrast, out of 7 million corresponding donor 536 stimulated PBMC sequences, 2,908 identical BCR sequences persisted across the three timepoints, of which the majority (2,151), were mutated IgG BCR sequences ([Figure 7](#F7){ref-type="fig"}). The BCR sequences had unique UMI usage between datasets, making it unlikely they were the result of cross-contamination. UMI codes are in the primers at the RT step where they are uniquely incorporated into a single cDNA. Also, the subsequent PCR reaction adds index primers to the UMI to differentiate reads between samples, further preventing incorrect sequence assignments downstream. It would be expected that, over this individual\'s lifetime, the sequences of many of these persistent clones, observed over a 9-month period, would change. Longitudinal studies would be useful to evaluate lifetime immune repertoires circulating in PBMC, and how these relate to Ig sequences in serum ([@B24]).

![Number of persistent sequences found in all three timepoints in a single donor, among PBMC or stimulated PBMC repertoires. Each column indicates the number of identical heavy chain sequences for IgM (black) or IgG (gray) sequences found across all three timepoints of donor 536, for PBMC or stimulated PBMC. Either total sequences or mutated sequences (\>1% SHM) are shown as indicated on the x-axis.](fimmu-10-01452-g0007){#F7}

Application of Stimulated PBMC Repertoire Data to Determine the Immunological Hierarchy of B Cell Clonal Memory
---------------------------------------------------------------------------------------------------------------

The deeper memory BCR repertoire data obtained from stimulated PBMCs allows for the identification of large clonal families related to known antigen-specific mAbs, making it possible to examine the expansion of antigen-specific mAbs in detail. For instance, we were able to map HA-specific mAbs onto lineages or networks of clonal families, highlighting aspects such as isotype, subtype and abundance (by reads per UMI). For example, the clonal lineage of HA stalk-region binding antibody INF9 is shown in [Figure 8](#F8){ref-type="fig"}. The representation was made using the Alakazam package in the Immcantation pipeline and is a parsimony-based network of the sequences clonally related to INF9 (in donor 536, single replicate of May timepoint), using data that could only be found in the stimulated PBMC repertoire, with the exception of a single sequence from the unstimulated PBMC repertoire, found near the bottom of the lineage. Within the lineage, INF9 itself appears as a minor member, with other BCR sequences having been selected for expansion and SHM divergence. Although IgM and IgA isotypes were observed, IgG dominated the response. We can also examine the relative abundances of antigen-specific mAb clonal families in stimulated PBMC repertoires. For example, using the stimulated May repertoire of donor 536, containing 1 million processed Ig sequences and a total of 127,448 clonal families (at the 12% clonal threshold), we created a heat map visualization of all clonal families ([Figure 9](#F9){ref-type="fig"}) plotted with SHM on the y-axis and the abundance (reads per clonal family) on the x-axis. The color indicates the number of clonal families in the dataset with a particular SHM/abundance characteristic from high (bright pink) to low (light blue). After finding heavy chain clonal families for 7/8 mAbs, we mapped their values for average SHM and abundance onto the heat map ([Figure 9](#F9){ref-type="fig"}). In this example, mAb INF9 has the most abundantly expressed clonal family of the 8 antigen-specific mAbs, containing 166 different sequences, and a 3% average SHM. In comparison, mAb INF12 shows the highest average SHM (12%) and low abundance (1 sequence) in the May repertoire. Despite being of low abundance in the May stimulated PBMC repertoire, sequences of variable read counts per UMI related to INF12 were found across all timepoints, indicating its persistence (data not shown). With more sample data and extensive mAb mapping, it may be possible to assess the relative immunodominant hierarchy of B cell clonal memory *in vivo*, which could be correlated to past and future protection from disease and guide vaccine design.

![Clonal family lineage of Influenza A HA^+^ memory B cell mAb INF9. **(A)** The clonal lineage of mAb INF9 deriving from the germline (IGHV3-30-3) in black, with IgG sequences in steel blue, IgM/IgG sequences (i.e., identical except for constant region) in light blue, IgG/IgA sequences in royal blue, one IgA sequence in red, and reference mAb B cell sequence INF9 shown in gray. White dots indicate putative sequences not found. INF87, found toward the bottom of the lineage and shown in gray, is another memory B cell sequence cloned after HA^+^ FACS but not tested to confirm HA-binding. The sizes indicate the relative read count per UMI. The sequences in this lineage were pooled from two replicates each of the PBMC and stimulated PBMC repertoires from the May 2018 timepoint of donor 536. Only a single sequence, shown as a square at the bottom of the lineage was derived from the unstimulated PBMC. This sequence was different by two nucleotides but identical at the amino acid level to INF87. The lineage was made using the Alakazam R scripts in the Immcantation pipeline, with a parsimony-based approach. Numbers between sequences indicate mutational steps at the nucleotide level. **(B)** An amino acid alignment of variable heavy chain sequences selected from the clonal family lineage shown in A. Somatic hypermutation from germline in the CDR1, CDR2, and CDR3 regions are shown in red and in the framework (FR) regions in orange. The reference mAb INF9 is shown on the bottom line, in bold.](fimmu-10-01452-g0008){#F8}

![Immunodominance plot of the May stimulated PBMC repertoire of donor 536. Clonal families of mAb IGVH sequences were found and plotted onto a heat map made from the total May IGVH clonal repertoire. The number of unique clonal families in the May IGVH repertoire at a given abundance and average SHM is indicated using a color scale, ranging from pinks for \>1,000 unique clonal families to blues for \<10 unique clonal families. Since the heat map plots all clonal families from the repertoire at a given abundance and average SHM, individual mAb clonal family diversity cannot be interpreted by color. The y-axis shows the average somatic hypermutation of clonal families and the x-axis the abundance of clonal families by number of sequencing reads. Because whole numbers are plotted using a log scale on the x-axis, this gives rise to an appearance of gaps between the lowest values. The plot was made using the Alakazam R scripts in the Immcantation pipeline.](fimmu-10-01452-g0009){#F9}

Discussion {#s4}
==========

There is an ongoing need for the development of improved vaccines to replace those that have high production costs, poor stability, efficacy, and/or durability as well as a need for research to inform new vaccines for intractable or emerging pathogens. Even for the most successful vaccines, continued vaccination of global populations and surveillance is often necessary to offset the re-emergence of diseases after incomplete geographical or lifespan coverage of immune protection. Furthermore, the natural evolution of pathogens to new or vaccine resistant strains provides an ongoing challenge to protective strategies. An ideal vaccine would provide robust, directed immunogenicity to give rise to dominant clones of high affinity antibodies with specificity, cross-reactivity and pathogen neutralizing or clearing activity. Importantly, clonal families for the corresponding antibody producing B cells would be found to be consistently well-represented in the memory compartment, with the ability to be rapidly and functionally activated upon subsequent exposures.

In this paper, we provide methods to allow for a deep analysis of the clonal diversity, persistence and hierarchy of antibodies in the memory repertoire from PBMCs. Our approach paralleled that of ELISPOT methods used to track vaccinations, whereby memory B cells are polyclonally differentiated into antibody secreting cells and expanded within the autologous PBMC environment. By comparing PBMC repertoire data in three healthy donors before and after stimulation, we showed the corresponding memory B cell Ig mRNA was better represented in amplicon pools of PBMC after stimulation, which are otherwise dominated by naïve, less antigen experienced B cell sequences. Definitive memory phenotype characteristics are lost upon B cell activation and we were not able to characterize single memory B cells from stimulated PBMCs. Instead, to support that the repertoire sequences we enriched for were from memory cells, we cloned single, antigen-specific memory B cells by standard cell surface FACS markers and demonstrated the mAb clonal family sequences could be more readily identified and found at greater depth in the stimulated PBMC repertoires. Furthermore, we were able to use the richer clonal family data to rank the immunodominance of mAbs. Such ranking could provide an informative tool to quantify the functional quality and direction of an immune response, such as in our examples, toward known neutralizing epitopes on the Influenza A hemagglutinin stalk region.

The correlation between the *in vitro* stimulation methods used here and functional *in vivo* memory B cell lineages is not known. Understanding how antigen-dependent and independent signals co-operate *in vivo* to maintain, activate and eliminate B cell populations is challenged by the complex and contextual environment of immune responses and regulation. Nevertheless, several lines of evidence in our data support that *in vitro* stimulation is not simply expanding clonal families by random SHM: (i) among identical V-D-J sequences (at the nucleotide level) found in repertoires of the same donor over time, a higher fraction were mutated IgG in stimulated PBMCs (74%) vs. PBMCs (2%); (ii) identical and near identical V-D-J sequences are found matching memory B cell, antigen-specific monoclonal antibodies isolated by FACS from the same individuals PBMC; (iii) sequences matching those in (ii) are found in repertoires of different blood draws taken over time from a given donor; (iv) sequences matching those in (ii) are found with a 10-fold or greater read number in stimulated PBMC which would correlate with increased cell proliferation and/or mRNA transcription in the absence of SHM; (v) sequences from stimulated PBMC are frequently distributed in clonal lineages closer to the germline, with fewer mutations than the reference mAbs; and (vi) highly cross-reactive viral-binding mAbs isolated during the acute phase of a secondary infection map to large clonal expansions and to distal points of clonal family lineages in acute phase stimulated PBMCs from within the same patient and, with lower frequency, among different patients (manuscript in preparation). To better understand *in vitro* stimulated lineages we are currently making and testing the activity of a variety of VH mutations obtained by NGS in these acute phase samples, paired with the reference mAb light chain. Notably, calculations using the Immcantation pipeline on our stimulated PBMC NGS data also provide a means to estimate mAbs in the context of the overall number of clonal families attributed to human memory B cells in blood. We observed in the range of six to twenty thousand clonal families for IgG memory among the three donors, while previous work has estimated the plasma cell derived clonal repertoire size in serum to be on the order of 20,000 ([@B24]). Additional data analysis is warranted to capture the variability between replicates and a statistical saturation point. Applying the new Immcantation tool called Repertoire Dissimilarity Index \[RDI; ([@B25])\], we determined RDI scores based on heavy chain V-gene usage (without D and J) between our replicates of 2.26 in PBMC repertoires and 2.36 in stimulated PBMC repertoires, suggesting the repertoires were not fully sampled. The methods for how threshold values are determined and applied to calculate and compare clonal families is an area warranting further study, and *in vitro* expansions of clonal families will offer deeper data sets for testing. In future studies, it will be of interest to compare the repertoire of polyclonal *in vitro* stimulation of B cell memory with larger sets of antigen-specific mAbs, and to use that data to identify public (many donor) vs. private (individual donor) sequences. Overall, the analysis of deep functional memory repertoires *in vitro* will provide for a better view of the *in vivo* landscape of humoral protection or enhancement of disease, informative to vaccine, autoimmune and therapeutic antibody research.

Clonal expansions of B cells occur in response to specific immune stimulation and evidence for a corresponding convergence of germline gene arrangements has been shown \[e.g., ([@B23]--[@B27])\]. Clonal families represent *in vivo* antibody molecular evolution to a consensus directed against common epitopes of vaccines or disease. As the field gains more and more knowledge on immune repertoires and collects data on responses to disease and vaccination, we will get closer to being able to deliberately direct our immune system toward epitopes yielding positive health outcomes.
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